[go: up one dir, main page]

WO2001092290A3 - Ganesin, an 18-residue cysteine-rich defense peptide from spider and related antinicrobial papdides, their preparation and uses. - Google Patents

Ganesin, an 18-residue cysteine-rich defense peptide from spider and related antinicrobial papdides, their preparation and uses. Download PDF

Info

Publication number
WO2001092290A3
WO2001092290A3 PCT/BR2001/000070 BR0100070W WO0192290A3 WO 2001092290 A3 WO2001092290 A3 WO 2001092290A3 BR 0100070 W BR0100070 W BR 0100070W WO 0192290 A3 WO0192290 A3 WO 0192290A3
Authority
WO
WIPO (PCT)
Prior art keywords
papdides
ganesin
antinicrobial
spider
rich
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2001/000070
Other languages
French (fr)
Other versions
WO2001092290A2 (en
Inventor
Sirlei Daffre
Da Silva Pedro Ismael Jr
Philippe Bulet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Sao Paulo USP
Centre National de la Recherche Scientifique CNRS
Original Assignee
Universidade de Sao Paulo USP
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Sao Paulo USP, Centre National de la Recherche Scientifique CNRS filed Critical Universidade de Sao Paulo USP
Priority to AU63676/01A priority Critical patent/AU6367601A/en
Publication of WO2001092290A2 publication Critical patent/WO2001092290A2/en
Publication of WO2001092290A3 publication Critical patent/WO2001092290A3/en
Anticipated expiration legal-status Critical
Priority to US11/432,286 priority patent/US7723468B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
PCT/BR2001/000070 2000-05-29 2001-05-29 Ganesin, an 18-residue cysteine-rich defense peptide from spider and related antinicrobial papdides, their preparation and uses. Ceased WO2001092290A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU63676/01A AU6367601A (en) 2000-05-29 2001-05-29 Antimicrobial peptide, process to obtain a peptide and uses therefor
US11/432,286 US7723468B2 (en) 2000-05-29 2006-05-10 Antimicrobial peptide, compositions, and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0001870-8A BR0001870B1 (en) 2000-05-29 2000-05-29 Peptide, peptide production process, formulation comprising peptide, parasite, fungal and bacterial growth prevention method, method for inactivating gram-negative endotoxin
BRPI0001870-8 2000-05-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10296853 A-371-Of-International 2001-05-29
US11/432,286 Continuation-In-Part US7723468B2 (en) 2000-05-29 2006-05-10 Antimicrobial peptide, compositions, and uses therefor

Publications (2)

Publication Number Publication Date
WO2001092290A2 WO2001092290A2 (en) 2001-12-06
WO2001092290A3 true WO2001092290A3 (en) 2002-08-15

Family

ID=3944218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2001/000070 Ceased WO2001092290A2 (en) 2000-05-29 2001-05-29 Ganesin, an 18-residue cysteine-rich defense peptide from spider and related antinicrobial papdides, their preparation and uses.

Country Status (4)

Country Link
US (2) US20030186854A1 (en)
AU (1) AU6367601A (en)
BR (1) BR0001870B1 (en)
WO (1) WO2001092290A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
JP2014502152A (en) 2010-11-12 2014-01-30 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド Cancer treatment and diagnosis
HK1208039A1 (en) 2011-12-29 2016-02-19 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
WO2014144768A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
CA2906572A1 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
JP2018511594A (en) 2015-03-18 2018-04-26 マサチューセッツ インスティテュート オブ テクノロジー Selective MCL-1-binding peptide
WO2017004591A2 (en) 2015-07-02 2017-01-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
CA2995479A1 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
JP7105696B2 (en) 2016-02-29 2022-07-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Stapled Intracellular Targeting Antimicrobial Peptides to Treat Infections
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
JP7069126B2 (en) 2016-08-26 2022-05-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド BCL-W polypeptides and mimetics for the treatment or prevention of chemotherapy-induced peripheral neuropathy and deafness
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
EP3551213A4 (en) 2016-12-07 2020-11-04 The University of Chicago COMPOSITIONS AND METHODS FOR INHIBITION OF FOXP3
AU2018304230A1 (en) 2017-07-19 2020-02-06 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
WO2019090267A1 (en) * 2017-11-03 2019-05-09 The Regents Of The University Of California Methods and compositions useful for inhibiting growth of certain bacteria
CA3079758A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
CN120118207A (en) 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 Stable peptide-mediated targeted protein degradation
US11952432B2 (en) 2018-02-07 2024-04-09 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
EP3765852A1 (en) 2018-03-14 2021-01-20 Dana Farber Cancer Institute, Inc. Stabilized peptides for biomarker detection
EP3852783A1 (en) 2018-09-17 2021-07-28 Massachusetts Institute of Technology Peptides selective for bcl-2 family proteins
EP3962933A1 (en) 2019-04-18 2022-03-09 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
EP4077361A1 (en) 2019-12-16 2022-10-26 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
WO2021127493A1 (en) 2019-12-20 2021-06-24 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
KR20220148869A (en) 2020-03-04 2022-11-07 다나-파버 캔서 인스티튜트 인크. Structurally stabilized antiviral SARS-CoV-2 peptides and uses thereof
WO2021216845A1 (en) 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
WO2021222243A2 (en) 2020-04-27 2021-11-04 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
JP2023546561A (en) 2020-10-14 2023-11-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Chimeric conjugates and methods of use for degradation of viral and host proteins
EP4240395A1 (en) 2020-11-05 2023-09-13 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
IL311151A (en) 2021-09-08 2024-04-01 Dana Farber Cancer Inst Inc Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
US20250288658A1 (en) 2022-05-04 2025-09-18 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
EP4532513A1 (en) * 2022-05-27 2025-04-09 Fundación Privada Instituto De Salud Global Barcelona Cyclic peptides with antibacterial activity against multidrug resistant (mdr) pathogens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994306A (en) * 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EHRET-SABATIER L. ET AL.: "Characterization of novel cysteine-rich antimicrobial peptides from scorpion blood", J. BIOL. CHEM., vol. 271, no. 47, 22 November 1996 (1996-11-22), pages 29537 - 29544 *
OSAKI T. ET AL.: "Horseshoe crab hemocyte-derived antimicrobial polypeptides, tachystatins, with sequence similarity to spider neurotoxins", J. BIOL. CHEM., vol. 274, no. 37, 10 September 1999 (1999-09-10), pages 26172 - 26178 *
SILVA P.I. JR. ET AL.: "Isolation and characterization of Gomesin, an 18-residue cysteine-rich defense peptide from the spider acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family", J. BIOL. CHEM., vol. 275, no. 43, 27 October 2000 (2000-10-27), pages 33464 - 33470 *

Also Published As

Publication number Publication date
US20060276380A1 (en) 2006-12-07
BR0001870B1 (en) 2014-02-25
US20030186854A1 (en) 2003-10-02
AU6367601A (en) 2001-12-11
BR0001870A (en) 2002-01-02
WO2001092290A2 (en) 2001-12-06
US7723468B2 (en) 2010-05-25

Similar Documents

Publication Publication Date Title
WO2001092290A3 (en) Ganesin, an 18-residue cysteine-rich defense peptide from spider and related antinicrobial papdides, their preparation and uses.
DK2162462T3 (en) CXC-CHEMOKIN RECEPTOR-4 (CXCR4) ANTAGONISTIC POLYPEPTIDE
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
EP4517326A3 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
NO20071369L (en) Antimicrobial peptides comprising an arginine and / or lysine-containing motif
WO2006134340A3 (en) Oxyntomodulin analogues and their effects on feeding behaviour
WO2007148224A3 (en) Polypeptide
WO2005040192A3 (en) Human cathelicidin antimicrobial peptides
WO2007048857A8 (en) Use of tgf-$g(b)1 inhibitor peptides in the preparation of an immune response modulating agent
WO2008113536A8 (en) Neurotrophic peptides
WO2003074546A3 (en) Streptavidin-binding peptide
WO2001009175A3 (en) Plant defensin variants with modified cystein residues
WO2003039577A1 (en) Remedies for dry eye and diseases associated with dry eye
WO2006046239A3 (en) A thymus-specific protein
EP2135876A3 (en) Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotherapy
WO2004005339A3 (en) Cationic linear peptides having antibacterial and/or antifungal properties
WO2012015979A3 (en) Hmgb1-derived peptides enhance immune response to antigens
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
WO2006103101A3 (en) MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
WO2006090090A3 (en) Hiv epitopes and pharmaceutical composition containing same
WO2006123926A3 (en) Peptide composition for growing and/or culturing micro-organisms and/or cells
WO2003097677A3 (en) Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus
WO2005007682A3 (en) A peptide and a pharmaceutical composition, and their medical applications
WO2019059572A3 (en) Novel antimicrobial peptide derived from skate skin and use thereof
IL278346B2 (en) Pedf-derived peptides for promoting meibomian gland regeneration and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10296853

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP